Bupropion (Wellbutrin / Zyban): Uses, How It Works, Side Effects and Complete 2026 Guide
Bupropion is one of the most prescribed medicines in the United States — with over 25 million prescriptions written annually — yet it remains widely misunderstood. It occupies a unique position in psychopharmacology: it is simultaneously an FDA-approved antidepressant (sold as Wellbutrin), an FDA-approved smoking cessation aid (sold as Zyban), and the subject of a critical seizure-related safety history that shapes how it is prescribed today. Unlike the vast majority of antidepressants — which work primarily on serotonin — bupropion works through an entirely different neurochemical mechanism, which accounts for both its distinctive therapeutic benefits and its unique side effect profile.
For the right patient, bupropion offers a compelling combination: antidepressant efficacy comparable to SSRIs (selective serotonin reuptake inhibitors), without the sexual dysfunction, sedation, and weight gain that cause so many patients to stop their antidepressant prematurely. For patients trying to quit smoking, it addresses the neurochemical underpinnings of nicotine dependence directly — reducing craving through the same dopaminergic mechanism it uses to treat depression. For patients with both depression and nicotine dependence, it may address both simultaneously.
But bupropion also has two serious absolute contraindications — seizure disorders and eating disorders — and a black box warning for suicidality in young patients, that every prescriber and patient must understand before starting treatment.
This complete 2026 guide covers bupropion's mechanism of action, all FDA-approved indications, the SR vs XL formulation difference, correct dosing, the full side effect profile, critical contraindications, drug interactions, and how it compares to SSRIs and other antidepressants.
MedlinePlus provides comprehensive patient information on bupropion at: https://medlineplus.gov/druginfo/meds/a695033.html
How Bupropion Works — The NDRI Mechanism
Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). Understanding this mechanism explains why it works differently from SSRIs and why its side effect profile is so distinctive:
SSRI mechanism (for comparison):
Selective serotonin reuptake inhibitors — fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro) — block the reabsorption of serotonin into presynaptic neurons, increasing serotonin availability in the synaptic cleft. This is the most widely used antidepressant mechanism and is responsible for both the benefits (mood improvement) and characteristic side effects (sexual dysfunction, emotional blunting, weight gain, sedation) of SSRIs.
Bupropion's mechanism:
Bupropion inhibits the reuptake of norepinephrine (noradrenaline) and dopamine — not serotonin. By preventing the removal of these two neurotransmitters from synapses, bupropion increases their concentration in key brain circuits:
Norepinephrine — involved in attention, alertness, energy, and motivation; low norepinephrine levels are associated with the fatigue and cognitive slowing of depression
Dopamine — the "reward and pleasure" neurotransmitter; involved in motivation, concentration, and the reward circuits underpinning addiction; low dopamine is central to both the anhedonia (inability to feel pleasure) of depression and the craving of nicotine withdrawal
Additional mechanism — nicotinic receptor antagonism:
Bupropion also blocks nicotinic acetylcholine receptors — the receptors that nicotine targets in the brain. This has two effects: it reduces the dopamine release triggered by smoking a cigarette (reducing the reward of smoking), and it mimics some of the nicotine-like receptor activation that prevents withdrawal. This dual action is why bupropion is one of only three FDA-approved pharmacological treatments for smoking cessation (alongside nicotine replacement therapy and varenicline).
Why the NDRI mechanism matters clinically:
Because bupropion does not significantly affect serotonin, it avoids the serotonin-mediated side effects that cause most SSRI-related treatment discontinuation:
No sexual dysfunction — libido, arousal, and orgasm function are preserved; bupropion is sometimes added to SSRI therapy specifically to counteract SSRI-induced sexual dysfunction
No significant weight gain — bupropion is associated with mild weight loss (average 1–2 kg) rather than the weight gain common with SSRIs and SNRIs; this makes it particularly attractive for patients who are already overweight or weight-conscious
No sedation — bupropion is activating rather than sedating; it improves energy and alertness; this is beneficial for patients with fatigue-predominant depression but can worsen insomnia in some patients
FDA-Approved Indications
Bupropion has three FDA-approved indications, reflecting its two marketed formulations:
1. Major Depressive Disorder (MDD) — Wellbutrin brand:
FDA-approved for the acute treatment and maintenance treatment of major depressive disorder in adults. Bupropion is considered a first-line or second-line antidepressant depending on patient characteristics — it is specifically preferred when:
Sexual dysfunction from prior SSRIs is a concern
Weight gain or obesity is a concern
The patient has comorbid ADHD symptoms (off-label but evidence-based)
The patient requires concurrent smoking cessation support
The patient is a shift worker or has significant fatigue (activating profile)
2. Seasonal Affective Disorder (SAD) — Wellbutrin XL brand:
FDA-approved specifically for prevention of SAD (winter depression). Wellbutrin XL 150–300mg is started in autumn, before the seasonal onset of depressive symptoms, and continued until spring. This preventive indication is unique — most antidepressants are used reactively.
3. Smoking Cessation — Zyban brand:
FDA-approved as an aid to smoking cessation treatment. Zyban is the same bupropion molecule as Wellbutrin but marketed specifically for smoking cessation at the SR (sustained-release) 150mg dose. Start one week before the designated quit date to allow therapeutic levels to build up; continue for 7–12 weeks. Can be combined with nicotine replacement therapy (NRT) for greater effectiveness — combination bupropion + NRT produces higher quit rates than either alone.
SR vs XL — Understanding the Formulations
Bupropion is available in three formulations with different release profiles:
Formulation | Brand | Release Profile | Dosing Frequency | Indications | Max Daily Dose |
Immediate release (IR) | Generic only | Immediate — short duration | 3 times daily | MDD | 450mg |
Sustained release (SR) | Wellbutrin SR / Zyban / Generic | Released over 12 hours | Twice daily | MDD + Smoking cessation | 400mg |
Extended release (XL) | Wellbutrin XL / Aplenzin / Generic | Released over 24 hours | Once daily | MDD + SAD | 450mg |
Most prescribed formulation in 2026: Bupropion XL — once-daily dosing maximises adherence and is now standard practice for depression. SR (Zyban) is standard for smoking cessation.
Critical SR dosing rule: minimum 8 hours between SR doses — bupropion SR doses taken less than 8 hours apart significantly increase seizure risk by causing peak plasma concentration spikes.
Dosage — Complete Guide
For major depression (SR):
Week 1: 150mg SR once in the morning for 3 days, then 150mg SR twice daily (morning and midday — NOT evening, to avoid insomnia)
Week 2 onwards: increase to 150mg SR twice daily (most patients) or 200mg SR twice daily if needed
Maximum: 400mg/day SR (in divided doses, no single dose >200mg)
Clinical response typically visible at 4 weeks; full effect at 6–8 weeks
For major depression (XL):
Start: 150mg XL once daily in the morning
After 4 days: increase to 300mg XL once daily (the most common therapeutic dose)
If needed: increase to 450mg XL once daily after several weeks
Maximum: 450mg/day XL
For smoking cessation (SR/Zyban):
Start: 150mg SR once daily for days 1–3
Days 4 to end of treatment: 150mg SR twice daily (8+ hours between doses)
Duration: 7–12 weeks total
Set quit date 1 week after starting bupropion — on quit date, drug is at steady state
May combine with NRT for greater efficacy
For seasonal affective disorder (XL):
Start in early autumn (September–October): 150mg XL once daily
After one week: increase to 300mg XL once daily
Continue until spring (approximately April)
Taper dose before discontinuing in spring
Side Effects — Complete Profile
Common side effects:
Insomnia — the most common; bupropion is stimulating; take SR doses morning and midday (not evening); take XL dose in the morning; may reduce with time or dose reduction
Dry mouth — very common; stay well hydrated
Headache — usually transient; improves after the first 1–2 weeks
Nausea — take with food to minimise; usually resolves
Dizziness and agitation
Tremor — particularly at higher doses
Increased sweating
What bupropion typically does NOT cause (unlike SSRIs):
Sexual dysfunction — preserved libido and function
Significant weight gain — mild weight loss is more common
Sedation — the opposite; bupropion is activating
Serious side effects requiring medical attention:
Seizures — the most important safety concern:
Bupropion was temporarily withdrawn from the US market in 1986 due to seizure-related adverse events at the higher doses used in early clinical trials. It was reintroduced in 1989 with revised dosing guidelines establishing the dose-dependent seizure risk:
Seizure incidence at therapeutic doses (up to 300mg/day): approximately 0.1% — comparable to other antidepressants
At doses above 300mg/day: risk rises sharply — approximately 0.4% at 400mg/day
At doses above 450mg/day: risk increases substantially further
Factors that increase seizure risk beyond dose:
Bulimia nervosa or anorexia nervosa — absolute contraindication; patients with eating disorders have a dramatically elevated seizure risk with bupropion — believed to be related to electrolyte abnormalities; one of the two absolute contraindications
Abrupt discontinuation of alcohol or benzodiazepines — already seizure-lowering threshold; bupropion further increases risk
History of seizure disorder — absolute contraindication
Head trauma
Concurrent use of other drugs that lower seizure threshold (tricyclic antidepressants, antipsychotics, tramadol, theophylline)
Black box warning — suicidality in young patients:
Like all antidepressants, bupropion carries an FDA black box warning: increased risk of suicidal thinking and behaviour in children, adolescents, and young adults (under 25) during initial treatment, particularly in the first 1–2 months. This does not mean bupropion causes suicidality in most patients — the evidence is complex and controversial — but it mandates close monitoring and frequent follow-up in young patients starting treatment, particularly in the first 4 weeks.
The warning does not apply to adults over 25 and antidepressants actually reduce suicidality in adults over 25 and especially in older adults.
Critical Drug Interactions
Interacting Drug / Class | Risk | Mechanism | Recommendation |
MAO inhibitors (phenelzine, selegiline, linezolid) | SEVERE — potentially fatal | Risk of hypertensive crisis and serotonin syndrome | 14-day washout before and after bupropion; absolute contraindication |
Tramadol | High — seizure risk | Both lower seizure threshold; tramadol also weakly serotonergic | Avoid combination; if unavoidable, use lowest doses under specialist supervision |
Tricyclic antidepressants (amitriptyline) | High — seizure and cardiac risk | Bupropion inhibits CYP2D6 — raises tricyclic levels | Monitor TCA levels; reduce TCA dose |
SSRIs / SNRIs (fluoxetine, venlafaxine) | Moderate — seizure + serotonin | Additive seizure risk; bupropion + SSRI interaction via CYP2D6 | Commonly combined but requires awareness; avoid high doses |
Antipsychotics (haloperidol, clozapine) | Moderate — seizure risk | Lower seizure threshold | Use lowest effective doses |
Alcohol | Moderate — seizure risk | Abrupt alcohol withdrawal with bupropion is high risk | Avoid heavy alcohol use; do not abruptly stop heavy drinking while on bupropion |
Carbamazepine / phenytoin (CYP2B6 inducers) | Moderate — reduces bupropion levels | CYP2B6 induction increases bupropion metabolism | May need dose adjustment |
Warfarin | Moderate | CYP enzyme interaction can alter warfarin metabolism | Monitor INR when starting or stopping bupropion |
Ritonavir / lopinavir (CYP2B6 inhibitors) | Moderate — raises bupropion levels | Reduced bupropion metabolism | Monitor for enhanced side effects and seizure risk |
Bupropion vs SSRIs — When to Choose Which
Feature | Bupropion (NDRI) | SSRIs (e.g. sertraline, escitalopram) |
Primary mechanism | Norepinephrine + dopamine reuptake inhibition | Serotonin reuptake inhibition |
Sexual dysfunction | Minimal — significant advantage | Common — 30–40% of patients |
Weight effect | Mild weight loss | Weight gain — common long-term |
Sedation | Activating — may cause insomnia | Variable — often sedating |
Anxiety | May worsen anxiety initially | Generally reduces anxiety |
Energy and motivation | Improves significantly | Variable |
Anhedonia (inability to feel pleasure) | Targets directly via dopamine | Less direct effect |
Smoking cessation | FDA-approved | No |
Seizure risk | Yes — dose-dependent | Very low |
ADHD comorbidity | Beneficial (off-label) | Not beneficial |
Best for | Low energy, anhedonia, weight-concerned, sexual dysfunction history, ADHD comorbidity, smokers | Anxiety comorbidity, agitation, general depression |
For our complete guide on anxiety disorders — bupropion is not first-line for anxiety and may worsen anxiety initially; SSRIs and SNRIs are preferred for anxious depression: [Anxiety Disorders: Types, Symptoms, Causes and Treatment]
For our complete guide on nicotine replacement therapy — bupropion and NRT can be combined for better smoking cessation outcomes: [Nicotine Replacement Therapy for Quitting Smoking: Complete 2026 Guide]()
For our guide on sleep deprivation — bupropion can worsen insomnia; understanding sleep hygiene helps manage this common side effect: [Sleep Deprivation and Driving Safety: How Fatigue Affects Health]()
Mayo Clinic provides the complete bupropion patient guide including all formulations and dosing at: https://www.mayoclinic.org/drugs-supplements/bupropion-oral-route/description/drg-20062478
Drugs.com provides the current bupropion professional monograph and interaction checker at: https://www.drugs.com/bupropion.html
Frequently Asked Questions
What is the difference between Wellbutrin and Zyban?
Wellbutrin and Zyban contain the same active ingredient — bupropion — but are marketed for different FDA-approved indications. Wellbutrin is prescribed for major depressive disorder and seasonal affective disorder. Zyban is marketed specifically for smoking cessation. Both use the sustained-release (SR) or extended-release (XL) formulation. The therapeutic dose for smoking cessation is 150mg SR twice daily — the same as a moderate antidepressant dose — which is why bupropion can simultaneously address depression and smoking cessation in patients who need both. The branding distinction has largely been superseded by generic bupropion prescribing, where the indication is determined by the prescriber.
Is bupropion safe for patients with anxiety?
Bupropion is not first-line for anxiety disorders and can worsen anxiety and agitation in some patients — particularly in the first 1–4 weeks of treatment. This is consistent with its activating mechanism (dopaminergic and noradrenergic stimulation can temporarily increase arousal). Patients with anxiety comorbidity should be counselled about this and started at the lowest available dose with gradual titration. SSRIs and SNRIs are generally preferred as first-line antidepressants when anxiety is the predominant comorbidity. Bupropion may be suitable as an add-on or alternative for patients whose anxiety is well-controlled but who have significant anhedonia, fatigue, or sexual dysfunction from prior SSRI treatment.
Why is bupropion contraindicated in eating disorders?
Patients with bulimia nervosa or anorexia nervosa have an absolute contraindication to bupropion. The reason is a dramatically elevated seizure risk in this population — believed to be related to the electrolyte disturbances (hypokalaemia, hyponatraemia, hypomagnesaemia) caused by purging behaviours in bulimia and malnutrition in anorexia. These electrolyte abnormalities lower the seizure threshold substantially, and bupropion's inherent seizure-lowering effect compounds this to a clinically unacceptable risk. This contraindication applies even when eating disorder symptoms are currently in remission, if there is a documented history of either condition.
Does bupropion cause weight gain?
No — bupropion is the only commonly prescribed antidepressant associated with mild weight loss rather than weight gain. Average weight change in clinical trials is a loss of approximately 1–2 kg over 6–12 months of treatment. This contrasts with SSRIs (typically neutral to mild gain), tricyclics (typically significant gain), mirtazapine (significant gain), and paroxetine (significant gain). The weight-neutral to weight-reducing profile is one of bupropion's most clinically significant advantages and is particularly relevant for the large proportion of patients with depression who are already overweight or obese.
What should I do if I miss a bupropion dose?
For bupropion SR (twice daily): if you miss a morning dose, take it as soon as you remember — unless it is already past 4pm, in which case skip the missed dose and take the evening dose at the regular time. Do not double up doses. For bupropion XL (once daily): if you miss a dose, take it the same day if it is before 6pm. If it is evening, skip the missed dose and take the next day's dose at the regular morning time. Never take a double dose of bupropion — doubling the dose significantly increases seizure risk by causing peak plasma concentration spikes far above the therapeutic range.
Comments